Lupin Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LUPIN, and when can generic versions of LUPIN drugs launch?
LUPIN has two hundred and forty-five approved drugs.
There are nine US patents protecting LUPIN drugs. There are twenty-five tentative approvals on LUPIN drugs.
There are eighty-three patent family members on LUPIN drugs in twenty-four countries and seven hundred and thirty-three supplementary protection certificates in seventeen countries.
Summary for Lupin
International Patents: | 83 |
US Patents: | 9 |
Tradenames: | 200 |
Ingredients: | 180 |
NDAs: | 245 |
Patent Litigation for Lupin: | See patent lawsuits for Lupin |
PTAB Cases with Lupin as petitioner: | See PTAB cases with Lupin as petitioner |
Drugs and US Patents for Lupin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lupin | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 078043-001 | Jul 12, 2007 | BX | RX | No | No | ⤷ Subscribe | |||||
Lupin Ltd | BROMFENAC SODIUM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 202903-001 | Aug 15, 2023 | AT2 | RX | No | No | ⤷ Subscribe | |||||
Lupin Ltd | DROSPIRENONE | drospirenone | TABLET;ORAL | 216936-001 | Sep 30, 2024 | AB | RX | No | No | ⤷ Subscribe | |||||
Lupin Ltd | ESLICARBAZEPINE ACETATE | eslicarbazepine acetate | TABLET;ORAL | 211246-003 | Mar 27, 2024 | DISCN | No | No | ⤷ Subscribe | ||||||
Lupin Ltd | PREDNISOLONE ACETATE | prednisolone acetate | SUSPENSION/DROPS;OPHTHALMIC | 216935-001 | Aug 2, 2024 | AB | RX | No | No | ⤷ Subscribe | |||||
Lupin Ltd | PREGABALIN | pregabalin | CAPSULE;ORAL | 091040-003 | May 3, 2022 | DISCN | No | No | ⤷ Subscribe | ||||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. |
Expired US Patents for Lupin
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lupin | ANTARA (MICRONIZED) | fenofibrate | CAPSULE;ORAL | 021695-001 | Nov 30, 2004 | 7,863,331 | ⤷ Subscribe |
Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 7,473,710 | ⤷ Subscribe |
Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 5,795,564 | ⤷ Subscribe |
Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 7,256,310 | ⤷ Subscribe |
Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 6,083,993 | ⤷ Subscribe |
Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 5,225,183 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LUPIN drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | for Oral Suspension | 500 mg/5 mL | ➤ Subscribe | 2014-07-22 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
➤ Subscribe | Inhalation Solution | Eq. 0.015 mg base/2 mL | ➤ Subscribe | 2009-10-01 |
International Patents for Lupin Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Australia | 2009241858 | ⤷ Subscribe |
Japan | 2016166368 | ⤷ Subscribe |
Poland | 377336 | ⤷ Subscribe |
South Korea | 20200106100 | ⤷ Subscribe |
South Korea | 20100080865 | ⤷ Subscribe |
South Korea | 20110010742 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lupin Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1884242 | 1490057-5 | Sweden | ⤷ Subscribe | PRODUCT NAME: LURASIDONE, OPTIONALLY IN THE FORM OF LURASIDONE HYDROCHLORIDE; REG. NO/DATE: EU/1/14/913 20140327 |
1638574 | 2017C/067 | Belgium | ⤷ Subscribe | PRODUCT NAME: MIDOSTAURIN OU UN DE SES SELS (RYDAPT); AUTHORISATION NUMBER AND DATE: EU/1/17/1218 20170920 |
3141251 | 301099 | Netherlands | ⤷ Subscribe | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
2101777 | 93081 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125 |
1301519 | CA 2016 00012 | Denmark | ⤷ Subscribe | PRODUCT NAME: TENOFOVIRALAFENAMID ELLER ET SALT ELLER SOLVAT DERAF, I SAERDELESHED TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/15/1061/001-002 20151123 |
1467728 | SPC/GB16/025 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: SACUBITRIL/VALSARTAN, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/15/1058(NI) 20151123; UK PLGB 00101/1041 20151123; UK PLGB 00101/1042 20151123; UK PLGB 00101/1043 20151123 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.